March 15th 2024
A blood-based cell-free DNA (cfDNA) test was able to find patients at increased risk of colorectal cancer (CRC), advanced neoplasia, and advanced precancerous lesions.
Drug Resistance and Toxicity Mitigation Strategies: Optimizing the Role of the Pharmacist in Management of Patients With Chronic Myeloid Leukemia
2.0 Credits / Oncology
View More
Risks and Liabilities in Pharmacy Practice
1.0 Credit / Law
View More
Exploring the New Standard of Care for the Frontline Treatment of Non-Small Cell Lung Cancer: A Focus on Immunotherapy
1.5 Credits / Oncology, Pulmonology/Respiratory
View More
Optimizing the Use of Targeted Therapies for the Treatment of ROS1-Rearranged and KRAS-Mutant Non−Small Cell Lung Cancer
1.0 Credits / Oncology
View More
2022 ASH Annual Meeting Coverage—Recent Developments in Diffuse Large B-Cell Lymphoma: Insights and Application for Managed Care
1.0 Credit / Oncology
View More
An Article in the American Journal of Managed Care’s Evidence-Based Oncology: Navigating the Complexities of Frontline Immunotherapy in NSCLC
2 Credits / Oncology, Pulmonology/Respiratory
View More
CAR T-Cell Therapy Advances in Lymphoma: Implications for Managed Care
1.5 Credits / Hematology, Oncology
View More
Evidence-Based Oncology: Discerning Novel Approaches, Recent Advances, and the Managed Care Considerations for Targeted Treatments in CLL
2.0 Credits / Hematology, Oncology
View More
Precision Oncology in Practice: Transforming Non–Small Cell Lung Cancer Care Through Advanced Biomarker Testing
April 4, 2024 | 2:25 PM ET
View More
Ensuring the Safe, Effective, and Equitable Care of Patients With Advanced Endometrial Cancer: Strategies for Oncology Pharmacists
April 4, 2024 | 1:35 PM ET
View More
Navigating the Use of Bispecific Antibodies in Non-Hodgkin Lymphoma: Solutions to Enhance Community-Based Care
April 4, 2024 | 11:50 AM ET
View More
Finding Balance Between Advancement and Application: A Guide for Community Oncology Pharmacists on CAR T-Cell Therapies and Bispecific Antibodies in Multiple Myeloma
April 4, 2024 | 11:00 AM ET
View More
Navigating Myelofibrosis: Tailored Treatments and Holistic Patient Support
April 5, 2024 | 11:00 AM ET
View More
Leveraging Managed Care to Increase Access to BCMA-Directed Treatment and Equitable Care in Multiple Myeloma
1.5 Credits / Hematology, Oncology
View More
Leveraging Managed Care to Optimize Patient Outcomes in Acute Myeloid Leukemia
1.5 Credits / Hematology, Oncology
View More
New Pathways in Care for Myelofibrosis: Optimizing Treatment to Improve Outcomes
1.5 Credits / Hematology, Oncology
View More
Evidence and Managed Care Considerations for the Use of Novel Immunotherapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
1.5 Credits / Oncology
View More
Translating Progress in BCMA-Directed Therapy for Multiple Myeloma into Advances in Patient Care
1.0 Credit / Hematology, Oncology
View More
Ushering in a New Era of Targeted Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Focus on New and Emerging Antibody-Based Regimens
1.0 Credit / Hematology, Oncology
View More
Optimizing Outcomes for Older Patients With Acute Myeloid Leukemia: A Focus on Alternative Induction Regimens and Maintenance Therapy
1.0 Credit / Hematology, Oncology
View More
Treatment Strategies for Chronic Myeloid Leukemia and the Pharmacist’s Impactful Role
1.0 Credit / Hematology, Oncology
View More
Enhancing the Safety of Outpatient CAR T-Cell Administration in Relapsed/Refractory Lymphomas Through Pharmacist-Directed Initiatives
1.0 Credit / Hematology, Oncology
View More
Continuing the Conversation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Addressing Operational Challenges and Integrating New and Emerging Antibody-Based Regimens
1.0 Credit / Hematology, Oncology
View More
Optimizing Safe Use of Antibody-Drug Conjugates in Solid Tumors Through Pharmacist Interventions
1.0 Credit / Oncology
View More
Navigating Current and Emerging Treatment Options for Myelofibrosis After Frontline Failure
1.0 Credit / Oncology
View More
Optimizing Treatment of Early-Stage Breast Cancer and the Pharmacist’s Role in Managing Targeted Therapies
1.5 Credits / Oncology
View More
Targeted Therapies for Non-Small Cell Lung Cancer With ROS1 or KRAS Mutations and the Impact of Pharmacists’ Care
1.0 Credit / Oncology, Pulmonology/Respiratory
View More
Enhancing Care for Patients With Endometrial Cancer Through Pharmacist Interventions
1.0 Credit / Oncology, Women’s Health
View More
Investigating Novel Strategies for the Treatment of Metastatic Small Cell Lung Cancer After Frontline Treatment Failure
1.0 Credit / Oncology
View More
Managed Care Considerations on the Evolving Role of Bispecific Antibodies in Hematologic Malignancies
1.5 Credits / Hematology, Oncology
View More
FDA Requests Black Box Warning for Approved CAR-T Therapies Over Secondary Cancer Concern
January 24th 2024As per US law Section 505(o)(4), the manufacturers are required to make the requested changes, respond with a modified version of the requested changes for review, or respond with a rebuttal within 30 days of the FDA's ask.